Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) growth accelerates

Q1 FY2026 EPS (Basic) of $0.45 rose 492.1% year over year, ahead of the +69.8% change in trailing-twelve-month EPS (Basic). Sequentially, it fell 16.7% from the prior quarter.

Context

  • EPS (Basic) increased in 2 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 4 analysts of $7.46 (+277.0%) for the fiscal year ending Dec 2026, a step up from the -7.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0.45-16.7% QoQ
Last fiscal yearDec 2025
$1.98-7.5% YoY
LTMMar 2026
$2.37+69.8% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+492.1%+352.4%-139.7 pp
1 year-7.5%+277.0%+284.5 pp
3-year CAGR—+56.5%—
5-year CAGR+41.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
1.98 USD
Year-over-year change
-7.5%
4-year CAGR
-0.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 EPS (Basic) of $2.37 is the highest of the 3 companies compared; the peer median is -$19.37.
  • Its year-over-year change of +69.8% is the 2nd highest of 3, against a peer median of -21.6%.
COLL Competitors Peer median
EPS (Basic) for COLL and competitors
Company Period LTM YoY 3-year CAGR
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$2.37 +69.8%—
PCRXPacira BioSciences, Inc.LTM Mar 2026$0.12 +105.4%-23.0%
SCLXScilex Holding CompanyLTM Mar 2026-$38.87 -148.5%—
LTGOLatigo Biotherapeutics Inc.—— ——
Peer median (excluding COLL) -$19.37-21.6%-23.0%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue276.87M463.93M566.77M631.45M780.57M
Cost of Revenue126.25M254.45M240.6M254.11M317.31M
Gross Profit150.62M209.49M326.17M377.34M463.26M
Gross Margin54.4%45.2%57.5%59.8%59.3%
Research & Development9.45M3.98M000
Selling, General & Admin118.96M172.19M159.21M182.98M276.17M
Operating Expenses132.99M176.17M159.21M207.45M276.17M
Depreciation & Amortization68.92M138.94M149.26M169.16M226.07M
EBITDA86.56M173.31M308.33M341.7M401.01M
EBITDA Margin31.3%37.4%54.4%54.1%51.4%
Operating Income17.63M33.32M166.96M169.9M187.08M
Operating Margin6.4%7.2%29.5%26.9%24.0%
Interest Income12K1.05M15.62M13.98M11.29M
Interest Expense21.01M63.21M83.34M73.97M82.31M
Other Income / Expenses(21M)(62.17M)(91.23M)(71.33M)(94.47M)
Income Before Tax(3.37M)(28.85M)75.73M98.57M92.62M
Pre-Tax Margin-1.2%-6.2%13.4%15.6%11.9%
Income Tax Expense(74.89M)(3.85M)27.58M29.38M29.75M
Net Income71.52M(25M)48.16M69.19M62.87M
Net Margin25.8%-5.4%8.5%11.0%8.1%
EPS (Basic)2.05(0.74)1.602.141.98
EPS (Diluted)1.86(0.74)1.291.861.73
Weighted Avg Shares34.94M33.83M33.74M32.27M31.71M
Weighted Avg Shares (Diluted)41.05M33.83M41.79M40.42M39.7M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.